Baird analyst Eric Coldwell lowered the firm’s price target on Cardinal Health to $128 from $134 and keeps an Outperform rating on the shares. The firm said they agree with management, other than Optum cliff event in 2025, it’s “full speed ahead.” Baird said the fact the Street favors other names and its history, diminishes the allure of value.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health Executives Discuss Quarterly Results and Future Projections
- Cardinal Health Reports Third Quarter Fiscal Year 2024 Results and Raises Fiscal Year 2024 Non-GAAP EPS Guidance
- Notable companies reporting before tomorrow’s open
- Cardinal Health Stock (NYSE:CAH): Dip Creates Long-Term Opportunity
- CAH Earnings Report this Week: Is It a Buy, Ahead of Earnings?